Gallbladder Cancer.
| Autor: | Marcinak CT; Division of Surgical Oncology, Department of Surgery, University of Wisconsin-Madison, 7375 Clinical Science Center, 600 Highland Avenue, Madison, WI, 53792, USA., Abbott DE; Division of Surgical Oncology, Department of Surgery, University of Wisconsin-Madison, 7375 Clinical Science Center, 600 Highland Avenue, Madison, WI, 53792, USA. abbott@surgery.wisc.edu. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cancer treatment and research [Cancer Treat Res] 2024; Vol. 192, pp. 147-163. |
| DOI: | 10.1007/978-3-031-61238-1_8 |
| Abstrakt: | Gallbladder carcinoma (GBC) is the most common biliary epithelial malignancy, with an estimated incidence of 1.13 cases per 100,000 in the United States (Hundal and Shaffer in Clin Epidemiol 6:99-109, 2014 1; Henley et al. in Cancer Epidemiol Biomarkers Prev 24:1319-1326, 2015 2). The insidious nature and late presentation of this disease place it among the most lethal invasive neoplasms. Gallbladder cancer spreads early by lymphatic or hematogenous metastasis, as well as by direct invasion into the liver. While surgery may be curative at early stages, both surgical and nonsurgical treatments remain largely unsuccessful in patients with more advanced diseases (Rahman et al. in Cancer Med 6:874-880, 2017 3). (© 2024. The Author(s), under exclusive license to Springer Nature Switzerland AG.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|